This is not the most recent version of the article. View current version (12 DEC 2012)

Intervention Review

Erythropoietin or Darbepoetin for patients with cancer

  1. Julia Bohlius1,*,
  2. Jayne Wilson2,
  3. Jerome Seidenfeld3,
  4. Margret Piper3,
  5. Guido Schwarzer4,
  6. Josie Sandercock5,
  7. Sven Trelle6,
  8. Olaf Weingart1,
  9. Susan Bayliss7,
  10. Susan Brunskill8,
  11. Benjamin Djulbegovic9,
  12. Charles Bennett10,
  13. Simon Langensiepen11,
  14. Chris Hyde8,
  15. Andreas Engert1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 19 JUL 2006

Assessed as up-to-date: 23 MAY 2006

DOI: 10.1002/14651858.CD003407.pub4


How to Cite

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Bennett C, Langensiepen S, Hyde C, Engert A. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003407. DOI: 10.1002/14651858.CD003407.pub4.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University of Birmingham, Dep. Public Health, Birmingham, UK

  3. 3

    Blue Cross and Blue Shield Association, Technology Evaluation Center, Chicago, IL, USA

  4. 4

    German Cochrane Center, Department of Medical Biometry and Statistics, Freiburg, Germany

  5. 5

    University of Birmingham, Dep Public Health, Birmingham, UK

  6. 6

    University of Bern, Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, Bern, Switzerland

  7. 7

    University of Birmingahm, Dep Public Health and Epidemilogy, Birmingham, UK

  8. 8

    NHS Blood and Transplant, Systematic Review Initiative, Oxford, Oxon, UK

  9. 9

    H. Lee Moffit Cancer Center and Research Institute, Department of Oncology, Tampa, Florida, USA

  10. 10

    VA Chicago Health Care System-Lakeside Division, Health Services Research and Development Program, Chicago, Illinois, USA

  11. 11

    University of Cologne, Department of Internal Medicine I, 50924 Cologne, Germany

*Julia Bohlius, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. julia.bohlius@uk-koeln.de. jbohlius@ispm.unibe.ch.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 JUL 2006

SEARCH

This is not the most recent version of the article. View current version (12 DEC 2012)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens

or

Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.